XBI vs. IBRN
XBI (SPDR S&P Biotech ETF) and IBRN (iShares Neuroscience and Healthcare ETF) are both Health & Biotech Equities funds - XBI tracks the S&P Biotechnology Select Industry Index while IBRN tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index. Both are passively managed. Over the past 3 years, XBI returned 15.65%/yr vs 12.41%/yr for IBRN. Their correlation of 0.88 suggests significant overlap in exposure. XBI charges 0.35%/yr vs 0.47%/yr for IBRN.
Performance
XBI vs. IBRN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, XBI achieves a 9.42% return, which is significantly higher than IBRN's 8.07% return.
XBI
- 1D
- 2.77%
- 1M
- -0.28%
- YTD
- 9.42%
- 6M
- 8.61%
- 1Y
- 62.35%
- 3Y*
- 15.65%
- 5Y*
- 1.14%
- 10Y*
- 8.53%
IBRN
- 1D
- 1.71%
- 1M
- -1.33%
- YTD
- 8.07%
- 6M
- 10.34%
- 1Y
- 52.90%
- 3Y*
- 12.41%
- 5Y*
- —
- 10Y*
- —
XBI vs. IBRN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
XBI SPDR S&P Biotech ETF | 9.42% | 35.89% | 1.01% | 7.60% | -2.40% |
IBRN iShares Neuroscience and Healthcare ETF | 8.07% | 28.49% | -2.78% | 0.92% | 5.85% |
Correlation
The correlation between XBI and IBRN is 0.90, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.90 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.88 |
Correlation (All Time) Calculated using the full available price history since Aug 29, 2022 | 0.88 |
The correlation between XBI and IBRN has been stable across timeframes, ranging from 0.88 to 0.90 - a consistent structural relationship.
XBI vs. IBRN - Sectors Allocation Comparison
Sectors
XBI
IBRN
Healthcare
Financial Services
-
Basic Materials
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
XBI
IBRN
Financial Services
XBI
IBRN
-
Basic Materials
XBI
IBRN
-
Communication Services
XBI
-
IBRN
-
Consumer Cyclical
XBI
-
IBRN
-
Consumer Defensive
XBI
-
IBRN
-
Energy
XBI
-
IBRN
-
Industrials
XBI
-
IBRN
-
Real Estate
XBI
-
IBRN
-
Technology
XBI
-
IBRN
-
Utilities
XBI
-
IBRN
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
XBI vs. IBRN — Risk / Return Rank
XBI
IBRN
XBI vs. IBRN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and iShares Neuroscience and Healthcare ETF (IBRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XBI | IBRN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.35 | ||
| Sortino ratioReturn per unit of downside risk | +0.37 | ||
| Omega ratioGain probability vs. loss probability | 1.40 | 1.34 | +0.06 |
| Calmar ratioReturn relative to maximum drawdown | 6.45 | 6.04 | +0.41 |
| Martin ratioReturn relative to average drawdown | 19.53 | 14.84 | +4.69 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| XBI | IBRN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.45 | 2.10 | +0.35 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.04 | — | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.27 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.36 | 0.41 | -0.04 |
Drawdowns
XBI vs. IBRN - Drawdown Comparison
The maximum XBI drawdown since its inception was -63.89%, which is greater than IBRN's maximum drawdown of -35.38%. Use the drawdown chart below to compare losses from any high point for XBI and IBRN.
Loading charts...
Drawdown Indicators
| XBI | IBRN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.89% | -35.38% | -28.51% |
Max Drawdown (1Y)Largest decline over 1 year | -9.72% | -8.80% | -0.92% |
Max Drawdown (3Y)Largest decline over 3 years | -32.99% | -35.38% | +2.39% |
Max Drawdown (5Y)Largest decline over 5 years | -54.71% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -63.89% | — | — |
Current DrawdownCurrent decline from peak | -22.89% | -3.19% | -19.70% |
Average DrawdownAverage peak-to-trough decline | -20.93% | -9.82% | -11.11% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.20% | 3.57% | -0.37% |
Volatility
XBI vs. IBRN - Volatility Comparison
SPDR S&P Biotech ETF (XBI) has a higher volatility of 9.69% compared to iShares Neuroscience and Healthcare ETF (IBRN) at 7.78%. This indicates that XBI's price experiences larger fluctuations and is considered to be riskier than IBRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| XBI | IBRN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.69% | 7.78% | +1.91% |
Volatility (6M)Calculated over the trailing 6-month period | 20.31% | 19.07% | +1.24% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.60% | 25.34% | +0.26% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.20% | 25.32% | +6.88% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.00% | 25.32% | +6.68% |
XBI vs. IBRN - Expense Ratio Comparison
XBI has a 0.35% expense ratio, which is lower than IBRN's 0.47% expense ratio.
Dividends
XBI vs. IBRN - Dividend Comparison
XBI's dividend yield for the trailing twelve months is around 0.33%, less than IBRN's 0.92% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IBRN iShares Neuroscience and Healthcare ETF | 0.92% | 0.99% | 0.40% | 0.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.33% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Frequently Asked Questions
XBI and IBRN have a correlation of 0.90, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
XBI has higher volatility (9.69%) compared to IBRN (7.78%). In terms of maximum drawdown, XBI dropped -63.89% vs IBRN's -35.38%.
On 3-year performance, XBI leads with 15.65% vs 12.41% for IBRN. On fees, XBI is cheaper at 0.35% per year. On volatility, IBRN has been the lower-risk option at 7.78%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 3-year period, XBI has performed better with a 15.65% return vs 12.41%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
XBI is cheaper with a 0.35% expense ratio, compared with 0.47% for IBRN.
IBRN has the higher dividend yield at 0.92%, compared with 0.33% for XBI.
XBI tracks S&P Biotechnology Select Industry Index, while IBRN tracks NYSE FactSet Global Neuro Biopharma and MedTech Index. They also come from different issuers: State Street and iShares. Their fees differ too: 0.35% for XBI and 0.47% for IBRN.
XBI currently has the higher Sharpe Ratio (2.45 vs 2.10), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for XBI and IBRN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer